HGH Fragment 176–191 – Research Peptide Derived from Human Growth Hormone
Synthetic peptide for research into lipid metabolism, lipolysis, energy regulation and connective tissue regeneration.
Che cos’è HGH Fragment 176–191
HGH Fragment 176–191 is a synthetic peptide derived from human growth hormone (HGH), representing a modified version of the hormone with targeted lipolytic effects. It is commonly known as the “lipolytic fragment” for its ability to promote fat degradation and regulate energy metabolism in animal research models. This peptide was developed to preserve the metabolic benefits of HGH while eliminating unwanted effects such as increased IGF-1 levels, bone or muscle growth, and altered insulin sensitivity.
Mechanism of Action and Biochemical Role
strong>Fragment 176–191 acts as the C-terminal portion of HGH, responsible for its lipolytic and hypoglycemic effects. Laboratory studies have shown that this fragment maintains the ability to stimulate fat burning and inhibit the formation of new adipose deposits without negatively affecting glucose levels or hormonal regulation. In animal models predisposed to obesity, the peptide produced a significant reduction in fat mass and an increase in metabolic activity, reducing lipid accumulation and improving cellular energy efficiency.
Experiments conducted on genetically modified mice confirmed that the fragment’s activity is mediated by beta-3 adrenergic receptors (ADRB3), which directly regulate lipolysis in adipose tissue and thermogenesis in skeletal muscle. However, the lipolytic effect of the peptide has also been observed in the absence of ADRB3, suggesting the existence of secondary metabolic pathways involved in energy balance and caloric expenditure.
Effects on Lipolysis and Body Weight
In obese murine models, HGH Fragment 176–191 has been shown to reduce body weight by up to 50% over a three-week treatment period compared to saline-treated controls. This effect was observed exclusively in obese animals, while lean mice exhibited no significant changes in body weight, indicating a selective action on excess adipose tissue.
This selective behavior opens new perspectives for the study of energy homeostasis, demonstrating that the fragment acts only when the organism presents abnormal lipid accumulation, without interfering with normal physiological metabolic processes. Results also suggest that the peptide’s activity may be linked to the activation of mitochondrial lipid metabolism and regulation of beta-oxidation.
Hypoglycemic Effects and Glucose Regulation
In vitro and in vivo research has shown that the C-terminal portion of HGH, from which Fragment 176–191 is derived, is responsible for most of the hormone’s hypoglycemic effects. Among the various fragments studied, 176–191 has proven to be the most effective in reducing blood glucose levels through a secondary and sustained increase in plasma insulin levels.
These findings have led researchers to explore the peptide’s potential use in studying glycemic regulation, prediabetes, and type 2 diabetes, although its applications remain strictly confined to the scientific and laboratory research setting.
Cartilage and Connective Tissue Regeneration
While the primary scientific focus on Fragment 176–191 has been its role in lipid metabolism, more recent studies have investigated its potential in cartilage regeneration. A 2015 study conducted in South Korea demonstrated that the fragment can enhance the effects of hyaluronic acid (HA) injections in promoting joint tissue growth and recovery.
In animal models, weekly injections of Fragment 176–191 increased markers of cartilage regeneration, while the combination with HA further amplified the results, showing improved mobility and a reduction in the clinical signs of osteoarthritis. These findings have opened new research pathways on the role of HGH fragments in joint repair and tissue reconstruction.
Safety Profile and Tolerability
One of the main strengths of Fragment 176–191 is its strong safety profile. Double-blind, placebo-controlled clinical studies have demonstrated that both oral and intravenous administration did not alter physiological or metabolic parameters. No changes were observed in glucose levels, glucose tolerance, insulin sensitivity, or IGF-1 values. Moreover, no significant adverse effects such as headache or edema were reported.
These observations suggest that the fragment offers many of the metabolic benefits of HGH without the side effects associated with its prolonged use, such as insulin resistance, acromegaly, or hypertension. In animal models, the peptide showed no anabolic or proliferative activity, ensuring a stable and safe experimental profile.
Future Research Directions
Scientific interest in HGH Fragment 176–191 remains focused on three main areas: lipolysis, energy regulation, and connective tissue regeneration. Current studies aim to better understand how the fragment influences energy homeostasis, lipid metabolism, and cell recovery processes. Its biological selectivity makes it a valuable research model for exploring controlled fat-loss mechanisms without altering systemic hormonal balance.
The product is intended exclusively for scientific research and is not approved for human or veterinary use. All information provided is for educational and laboratory purposes only.
